A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 673 participants.

Also called NCT06200207

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 673 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06200207
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Bulgaria, Canada, Czechia, France, Germany, Greece, India, Malaysia, Poland, Portugal, Spain, Türkiye, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06200207. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-01 (actual); primary completion 2026-10-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
Acronym
ATHENA
Condition
Heart Failure
Condition
Systemic Inflammation
Intervention (Drug)
Ziltivekimab
Intervention (Drug)
Placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct06200207
Content hash
e810a2a01aa734979cb2dda6b1694841a574240f3a120951f17ea477fe4a00dd